Song Xingyu, Zhang Yaheng, Yang Hongtao, Xiong Fujun, Chen FengFeng
Department of Orthopaedics, Xi'an Daxing Hospital, Xi'an, Shaanxi Province, China.
Medicine (Baltimore). 2025 May 30;104(22):e42668. doi: 10.1097/MD.0000000000042668.
In recent years, the widespread application of glucocorticoids in the medical field has led to a notable rise in the incidence of glucocorticoid-induced osteoporosis (GIOP). Currently, glucocorticoid-induced osteoporosis has emerged as the third leading cause of osteoporosis, following senile osteoporosis and postmenopausal osteoporosis. Scientific investigations have demonstrated that glucocorticoids exert a dual-pronged negative impact on bone metabolism. On one hand, glucocorticoids inhibit osteoblasts proliferation, trigger osteoblasts apoptosis, and undermine their osteogenic potential. On the other hand, glucocorticoids enhance osteoclasts proliferation and extend osteoclasts lifespan. Additionally, glucocorticoids can indirectly impede osteogenic differentiation by disrupting the balance of relevant cytokines and compromising the blood supply to bone tissue. This article is a comprehensive review of the latest research findings and treatment advances in the field of glucocorticoid-induced osteoporosis.
近年来，糖皮质激素在医学领域的广泛应用导致糖皮质激素性骨质疏松症（GIOP）的发病率显著上升。目前，糖皮质激素性骨质疏松症已成为继老年性骨质疏松症和绝经后骨质疏松症之后的第三大骨质疏松症病因。科学研究表明，糖皮质激素对骨代谢产生双重负面影响。一方面，糖皮质激素抑制成骨细胞增殖，引发成骨细胞凋亡，并削弱其成骨潜能。另一方面，糖皮质激素增强破骨细胞增殖并延长破骨细胞寿命。此外，糖皮质激素可通过破坏相关细胞因子的平衡并损害骨组织的血液供应来间接阻碍成骨分化。本文对糖皮质激素性骨质疏松症领域的最新研究成果和治疗进展进行了全面综述。
